Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial

Christine Johnston(University of Washington), Jared M. Baeten(University of Washington), Arun Raghav Mahankali Sridhar(University of Washington), Helen C. Stankiewicz Karita(University of Washington), Keith R. Jerome(University of Washington), Meei‐Li Huang(Infectious Disease Research Institute), Susan Morrison, Ruanne V. Barnabas(Harvard University), Sybil Hosek(University of Illinois Chicago), Hannah Leingang(University of Washington), Harald S. Haugen, Peter A. Noseworthy(Mayo Clinic in Arizona), Patricia Kissinger(Tulane University), Michael K. Paasche‐Orlow(Tufts Medical Center), Anna Wald(University of Washington), Temitope Oyedele(AstraZeneca (South Korea)), Michael J. Ackerman(Mayo Clinic), Jeanne E. Poole(Heart Rhythm Society), Mark H. Wener(University of Washington), Anna Bershteyn(New York University), Alexander L. Greninger(University of Washington), Kristopher Paolino(Walter Reed National Military Medical Center), Kate B. Heller(University of Washington), Joshua T. Schiffer(University of Washington), John Dwyer, Connie Celum(University of Washington), Elizabeth R. Brown(Fred Hutch Cancer Center), Helen Y. Chu(Seattle Pacific University), Tracy Qi Dong(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jenell Stewart(Hennepin Healthcare Research Institute)
EClinicalMedicine
February 27, 2021
Cited by 65


Related Papers